[go: up one dir, main page]

ATE496992T1 - Behandlung von igai-ablagerungserkrankungen - Google Patents

Behandlung von igai-ablagerungserkrankungen

Info

Publication number
ATE496992T1
ATE496992T1 AT04749338T AT04749338T ATE496992T1 AT E496992 T1 ATE496992 T1 AT E496992T1 AT 04749338 T AT04749338 T AT 04749338T AT 04749338 T AT04749338 T AT 04749338T AT E496992 T1 ATE496992 T1 AT E496992T1
Authority
AT
Austria
Prior art keywords
iga1
treatment
igai
deposition
deposition disease
Prior art date
Application number
AT04749338T
Other languages
English (en)
Inventor
Andrew Plaut
Jiazhou Qiu
Original Assignee
New England Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Inc filed Critical New England Medical Center Inc
Application granted granted Critical
Publication of ATE496992T1 publication Critical patent/ATE496992T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K6/00—Preparations for dentistry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/42—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a HA(hemagglutinin)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Epidemiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT04749338T 2003-03-07 2004-03-05 Behandlung von igai-ablagerungserkrankungen ATE496992T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45305503P 2003-03-07 2003-03-07
PCT/US2004/006615 WO2004096157A2 (en) 2003-03-07 2004-03-05 Treatment of igai deposition diseases

Publications (1)

Publication Number Publication Date
ATE496992T1 true ATE496992T1 (de) 2011-02-15

Family

ID=33418058

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749338T ATE496992T1 (de) 2003-03-07 2004-03-05 Behandlung von igai-ablagerungserkrankungen

Country Status (10)

Country Link
US (3) US7407653B2 (de)
EP (1) EP1603511B1 (de)
JP (4) JP5438886B2 (de)
KR (2) KR20130026513A (de)
CN (1) CN1777673B (de)
AT (1) ATE496992T1 (de)
CA (1) CA2558873C (de)
DE (1) DE602004031199D1 (de)
ES (1) ES2360291T3 (de)
WO (1) WO2004096157A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5438886B2 (ja) 2003-03-07 2014-03-12 タフツ メディカル センター インコーポレイテッド ＩｇＡ１沈着症の治療
US8440191B2 (en) 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
US20080027554A1 (en) * 2006-07-31 2008-01-31 Talmadge Karen D Kit and methods of treatment of an intervertebral disc
US20100261252A1 (en) * 2009-04-10 2010-10-14 Biomarin Pharmaceutical Inc. Methods of enhancing yield of active iga protease
WO2010123885A2 (en) * 2009-04-20 2010-10-28 Tufts Medical Center, Inc. Iga1 protease polypeptide agents and uses thereof
CN104073474A (zh) * 2014-06-27 2014-10-01 樊均明 一种IgA1酶及其制备方法和应用
WO2017223534A2 (en) * 2016-06-24 2017-12-28 Anthera Pharmaceuticals, Inc. Methods of treating iga nephropathy and henoch-schönlein purpura nephritis using a b-cell activating factor (baff) inhibitor
CN115197328B (zh) * 2021-04-09 2025-05-16 北京大学第一医院 一种可清除体内免疫球蛋白A的重组融合蛋白酶及其制备方法和在治疗IgA肾病中的应用
AU2023210789A1 (en) * 2022-01-29 2024-07-18 Peking University First Hospital Iga protease truncation, fusion protein comprising iga protease truncation, and use thereof
CN120475986A (zh) 2022-11-11 2025-08-12 艾甘生物科学有限公司 IgA蛋白酶多肽剂
JP7736395B1 (ja) * 2024-02-29 2025-09-09 積水メディカル株式会社 免疫学的測定方法、免疫学的測定用試薬、免疫学的測定用検体前処理液、免疫学的測定用試薬キット、及び非特異反応抑制剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DK130889A (da) * 1989-03-17 1990-09-18 Mogens Kilian Immunoglobulin a1-proteaser (iga1-proteaser), fremgangsmaade til genteknologisk fremstilling af saadanne enzymer samt vaccine indeholdende enzymerne og fragmenter deraf til immunisering mod bakteriel meningitis og andre sygdomme fremkaldt af iga1-protease-producerende bakterier
EP1069432B1 (de) * 1998-03-31 2008-05-21 Asahi Kasei Pharma Corporation VERFAHREN ZUR UNTERSUCHUNG DER IgA-NEPHROPATHIE
DE69940364D1 (de) 1999-05-18 2009-03-19 Dyax Corp Fab Fragmentbibliotheken und Verfahren für deren Verwendung
JP5438886B2 (ja) 2003-03-07 2014-03-12 タフツ メディカル センター インコーポレイテッド ＩｇＡ１沈着症の治療

Also Published As

Publication number Publication date
KR20130026513A (ko) 2013-03-13
US8216568B2 (en) 2012-07-10
EP1603511A4 (de) 2007-06-06
WO2004096157A2 (en) 2004-11-11
CA2558873C (en) 2015-10-20
US20050136062A1 (en) 2005-06-23
CA2558873A1 (en) 2004-11-11
JP2011101645A (ja) 2011-05-26
EP1603511A2 (de) 2005-12-14
US20090130084A1 (en) 2009-05-21
JP2006519619A (ja) 2006-08-31
ES2360291T3 (es) 2011-06-02
JP2013230157A (ja) 2013-11-14
JP5438886B2 (ja) 2014-03-12
CN1777673B (zh) 2010-04-28
CN1777673A (zh) 2006-05-24
WO2004096157A3 (en) 2005-10-20
US20090041746A1 (en) 2009-02-12
US7407653B2 (en) 2008-08-05
KR20060015468A (ko) 2006-02-17
EP1603511B1 (de) 2011-01-26
DE602004031199D1 (de) 2011-03-10
HK1090950A1 (zh) 2007-01-05
JP2015096079A (ja) 2015-05-21

Similar Documents

Publication Publication Date Title
ATE489957T1 (de) Mittel zur behandlung von entzündlichen erkrankungen
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
IS7925A (is) Hýdroxýetýlamínafleiður til að meðhöndla Alzheimers-sjúkdóm
WO2007022506A3 (en) Methods and compositions for treating neurological disease
NO20081084L (no) Arylpyridiner og fremgangsmater for deres anvendelse
ATE496992T1 (de) Behandlung von igai-ablagerungserkrankungen
TW200724157A (en) A non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
BR0312232A (pt) Inibidores de caspases e seus usos
WO2007089375A3 (en) Compositions and methods for regulating complement system
ATE390928T1 (de) Zusammensetzungen zur behandlung von hauterkrankungen
DE50109156D1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
NO20076186L (no) Mitotiske kinesininhibitorer og fremgangsmater for anvendelse derav
BR0214672A (pt) Inibidores de fosfolipase citosólica a2
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
GB0328900D0 (en) Novel compounds
IL174525A0 (en) Medicamentously targeted local lipolysis
MXPA05008561A (es) Uso de esteroides para tratar personas que sufren de trastornos oculares.
WO2004024089A3 (en) Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
WO2004056768A3 (en) Use of substituted 2,5-diamidoindoles for the treatment of urological diseases
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties